Literature DB >> 20425381

Large granular lymphocyte leukemia.

Lubomir Sokol1, Thomas P Loughran.   

Abstract

Clonal diseases of large granular lymphocytes (LGLs) represent a spectrum of clinically rare lymphoproliferative malignancies arising from either mature T-cell (CD3(+)) or natural killer (NK)-cell (CD3(-)) lineages. The clinical behavior of these disorders ranges from indolent to very aggressive. Patients with symptomatic indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies; in contrast, aggressive T-cell or NK-cell LGL leukemias require intensive chemotherapy regimens. Novel targeted therapies are currently being tested in clinical studies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 20425381     DOI： 10.1007/s11899-007-0038-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  36 in total

Review 1.  Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature.

Authors:  Todd J Alekshun; Jianguo Tao; Lubomir Sokol
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

Review 2.  T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.

Authors:  Nnenna Osuji; Estella Matutes; Geir Tjonnfjord; Henri Grech; Ilaria Del Giudice; Andrew Wotherspoon; John G Swansbury; Daniel Catovsky
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

3.  Aggressive variant of morphologically typical T large granular lymphocyte leukemia/lymphoma lacking NK cell markers.

Authors:  R Passetto Falcão ; B Pinto Simões ; A B Garcia; B A Fonseca; J Terra Filho
Journal:  Acta Haematol       Date:  2000       Impact factor: 2.195

4.  Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma.

Authors:  E Matutes; A C Wotherspoon; N E Parker; N Osuji; P G Isaacson; D Catovsky
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

Review 5.  Congenital and acquired neutropenia.

Authors:  Nancy Berliner; Marshall Horwitz; Thomas P Loughran
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

6.  Large Granular Lymphocyte Leukemia.

Authors: 
Journal:  Cancer Control       Date:  1998-01       Impact factor: 3.302

7.  Multiple lymphoid nodules in bone marrow have the same clonality as underlying myelodysplastic syndrome recognized with fluorescent in situ hybridization technique.

Authors:  W Mongkonsritragoon; L Letendre; C Y Li
Journal:  Am J Hematol       Date:  1998-11       Impact factor: 10.047

8.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.

Authors:  T Lamy; J H Liu; T H Landowski; W S Dalton; T P Loughran
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

Review 9.  Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Semin Hematol       Date:  2003-07       Impact factor: 3.851

Review 10.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Oncologist       Date:  2006-03
View more
  7 in total

1.  High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology.

Authors:  Ozlen Bektas; Aysegul Uner; Seda Muruvvet Aydin; Eylem Eliacik; Burak Uz; Ayse Işık; Ibrahim Celalettin Haznedaroğlu; Hakan Goker; Nilgun Sayinalp; Salih Aksu; Halûk Demiroglu; Osman Ilhami Ozcebe; Yahya Buyukasik
Journal:  Int J Hematol       Date:  2015-05-26       Impact factor: 2.490

2.  Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia.

Authors:  Jing Chen; Mike Petrus; Richard Bamford; Joanna H Shih; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

3.  Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.

Authors:  E Andersson; H Kuusanmäki; S Bortoluzzi; S Lagström; A Parsons; H Rajala; A van Adrichem; S Eldfors; T Olson; M J Clemente; A Laasonen; P Ellonen; C Heckman; T P Loughran; J P Maciejewski; S Mustjoki
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

4.  Identification of indels in next-generation sequencing data.

Authors:  Aakrosh Ratan; Thomas L Olson; Thomas P Loughran; Webb Miller
Journal:  BMC Bioinformatics       Date:  2015-02-13       Impact factor: 3.169

5.  Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation.

Authors:  E I Andersson; H L M Rajala; S Eldfors; P Ellonen; T Olson; A Jerez; M J Clemente; O Kallioniemi; K Porkka; C Heckman; T P Loughran; J P Maciejewski; S Mustjoki
Journal:  Blood Cancer J       Date:  2013-12-06       Impact factor: 11.037

6.  Emergence of a STAT3 mutated NK clone in LGL leukemia.

Authors:  Yiyi Yan; Thomas L Olson; Susan B Nyland; David J Feith; Thomas P Loughran
Journal:  Leuk Res Rep       Date:  2014-12-16

7.  Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions.

Authors:  Anna Lissina; James E McLaren; Mette Ilander; Emma I Andersson; Catherine S Lewis; Mathew Clement; Andrew Herman; Kristin Ladell; Sian Llewellyn-Lacey; Kelly L Miners; Emma Gostick; J Joseph Melenhorst; A John Barrett; David A Price; Satu Mustjoki; Linda Wooldridge
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.